RNA (Atrium Therapeutics) EBIT: $-65.32 Mil (TTM As of Mar. 2026)


RNA Atrium Therapeutics Inc RNA
12 GF Score
Price $12.94
! 1 Warning Sign
View Full Analysis

What is Atrium Therapeutics EBIT?

Atrium Therapeutics RNA +1.25% 12 EBIT is $-65.32 Mil as of Mar. 2026. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Atrium Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-17.28 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-65.32 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Atrium Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -251.91%. Atrium Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,162.85%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Atrium Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 149.04%.

Atrium Therapeutics  (NAS:RNA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Atrium Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-69.12 * ( 1 - 0% )/( (33.966 + 20.91)/ 2 )
=-69.12/27.438
=-251.91 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=278.353 - 13.343 - ( 270 - max(0, 41.801 - 272.845+270))
=33.966

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=292.36 - 7.79 - ( 267.849 - max(0, 21.905 - 285.565+267.849))
=20.91

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Atrium Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-69.12/( ( (5.508 + max(-35.284, 0)) + (6.38 + max(-1.509, 0)) )/ 2 )
=-69.12/( ( 5.508 + 6.38 )/ 2 )
=-69.12/5.944
=-1,162.85 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.845) - (13.343 + 21.639 + 3.147)
=-35.284

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15 + 0 + 2.716) - (7.79 + 9.344 + 2.091)
=-1.509

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Atrium Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-65.315/-43.824
=149.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics EBIT Related Terms

Atrium Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Atrium Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrium Therapeutics EBIT Chart

Atrium Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
EBIT
-6.39 -13.22 -76.81

Atrium Therapeutics Quarterly Data
Dec23 Dec24 Mar25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial -6.25 -7.45 0.00 -48.04 -17.28

RNA vs RNAC, KROS, ARCT: EBIT Comparison

For the Biotechnology subindustry, Atrium Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atrium Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Atrium Therapeutics's EV-to-EBIT falls into.


RNA
12GF Score
Atrium Therapeutics Inc RNA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrium Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-65.32 Mil mean?
Atrium Therapeutics (RNA) has a EBIT of $-65.32 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Atrium Therapeutics.
Is Atrium Therapeutics' EBIT too high?
Atrium Therapeutics' current EBIT is $-65.32 Mil. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' EBIT compare to RNAC and KROS?
Atrium Therapeutics' EBIT of $-65.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Atrium Therapeutics. Atrium Therapeutics's current EBIT is $-65.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current EBIT of $-65.32 Mil. The current EBIT is $-65.32 Mil. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current EBIT is $-65.32 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atrium Therapeutics Business Description

Address 10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score

Get the complete analysis for RNA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.94
Price